Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

FSGS is a potentially devastating form of nephrotic syndrome. Treatment of SRNS can be difficult, especially post-transplantation. The current therapy of post-transplant SRNS includes plasmapheresis, ACE-I, CNI, and monoclonal antibodies (rituximab). Patients who are refractory to these interventions have limited therapeutic alternatives. We present a case of a patient with SRNS secondary to FSGS. He did not respond to immunosuppressive medications prior to transplant, progressed to ESRD, and was started on chronic hemodialysis. He received a DDKT which was complicated by post-transplant FSGS recurrence. A course of plasmapheresis, rituximab, and CNI were administered with some response. Ofatumumab was then given to the patient. As a result, the patient achieved partial remission. Ofatumumab may be a safe and effective option for post-transplant recurrence of FSGS.

Original languageEnglish (US)
Article numbere13413
JournalPediatric Transplantation
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Focal Segmental Glomerulosclerosis
Transplantation
Transplants
Recurrence
Plasmapheresis
Nephrotic Syndrome
Immunosuppressive Agents
Chronic Kidney Failure
Renal Dialysis
Therapeutics
Monoclonal Antibodies
ofatumumab
Rituximab

Keywords

  • FSGS
  • Ofatumumab
  • Renal Transplant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

@article{510057e64a19400b865760055cca291a,
title = "Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child",
abstract = "FSGS is a potentially devastating form of nephrotic syndrome. Treatment of SRNS can be difficult, especially post-transplantation. The current therapy of post-transplant SRNS includes plasmapheresis, ACE-I, CNI, and monoclonal antibodies (rituximab). Patients who are refractory to these interventions have limited therapeutic alternatives. We present a case of a patient with SRNS secondary to FSGS. He did not respond to immunosuppressive medications prior to transplant, progressed to ESRD, and was started on chronic hemodialysis. He received a DDKT which was complicated by post-transplant FSGS recurrence. A course of plasmapheresis, rituximab, and CNI were administered with some response. Ofatumumab was then given to the patient. As a result, the patient achieved partial remission. Ofatumumab may be a safe and effective option for post-transplant recurrence of FSGS.",
keywords = "FSGS, Ofatumumab, Renal Transplant",
author = "Sonia Solomon and Zolotnitskaya, {Anna Y.} and {Del Rio}, Marcela",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/petr.13413",
language = "English (US)",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child

AU - Solomon, Sonia

AU - Zolotnitskaya, Anna Y.

AU - Del Rio, Marcela

PY - 2019/1/1

Y1 - 2019/1/1

N2 - FSGS is a potentially devastating form of nephrotic syndrome. Treatment of SRNS can be difficult, especially post-transplantation. The current therapy of post-transplant SRNS includes plasmapheresis, ACE-I, CNI, and monoclonal antibodies (rituximab). Patients who are refractory to these interventions have limited therapeutic alternatives. We present a case of a patient with SRNS secondary to FSGS. He did not respond to immunosuppressive medications prior to transplant, progressed to ESRD, and was started on chronic hemodialysis. He received a DDKT which was complicated by post-transplant FSGS recurrence. A course of plasmapheresis, rituximab, and CNI were administered with some response. Ofatumumab was then given to the patient. As a result, the patient achieved partial remission. Ofatumumab may be a safe and effective option for post-transplant recurrence of FSGS.

AB - FSGS is a potentially devastating form of nephrotic syndrome. Treatment of SRNS can be difficult, especially post-transplantation. The current therapy of post-transplant SRNS includes plasmapheresis, ACE-I, CNI, and monoclonal antibodies (rituximab). Patients who are refractory to these interventions have limited therapeutic alternatives. We present a case of a patient with SRNS secondary to FSGS. He did not respond to immunosuppressive medications prior to transplant, progressed to ESRD, and was started on chronic hemodialysis. He received a DDKT which was complicated by post-transplant FSGS recurrence. A course of plasmapheresis, rituximab, and CNI were administered with some response. Ofatumumab was then given to the patient. As a result, the patient achieved partial remission. Ofatumumab may be a safe and effective option for post-transplant recurrence of FSGS.

KW - FSGS

KW - Ofatumumab

KW - Renal Transplant

UR - http://www.scopus.com/inward/record.url?scp=85064488362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064488362&partnerID=8YFLogxK

U2 - 10.1111/petr.13413

DO - 10.1111/petr.13413

M3 - Article

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

M1 - e13413

ER -